Abciximab-induced thrombocytopenia: correct management

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

Journal of Experimental and Clinical Medicine
Volume:39 Issue:2
Abciximab-induced thrombocytopenia: correct management

Abciximab-induced thrombocytopenia: correct management

Authors : Engin KELKİTLİ, Aslı ODABAŞI GİDEN, Derya DENİZ KÜREKÇİ, Mehmet TURGUT

Pages : 581-583

View : 124 | Download : 13

Publication Date : 2022-03-18

Article Type : Other Papers

Abstract :Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors insert ignore into journalissuearticles values(along with eptifibatide and tirofiban); that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.
Keywords : Abciximab, glycoprotein IIb IIIa receptor inhibitors, side effect, thrombocytopenia

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.